Table 2 Patient and tumor characteristics.
| Â | Triple-negative | ER+/PR+/HER2- | Basal-like | Total |
|---|---|---|---|---|
T | Â | Â | Â | Â |
   1 | 11 (29.7%) | 25 (59.5%) | 6 (19.4%) | 36 (45.6%) |
   2 | 23 (62.2%) | 14 (33.3%) | 22 (71.0%) | 37 (46.8%) |
   3+4 | 3 (8.1%) | 3 (7.2%) | 3 (9.7%) | 6 (7.6%) |
Nodal status | Â | Â | Â | Â |
   Negative | 21 (56.8%) | 23 (54.8%) | 18 (58.1%) | 44 (55.7%) |
   Positive | 16 (43.2%) | 19 (45.2%) | 13 (41.9%) | 35 (44.3%) |
Ki-67 | Â | Â | Â | Â |
   Negative | 3 (8.1%) | 7 (16.7%) | 2 (6.5%) | 10 (12.7%) |
   Positive | 34 (91.9%) | 35 (83.3%) | 29 (93.5%) | 69 (87.3%) |
Grade | Â | Â | Â | Â |
   I | 0 (0.0%) | 8 (19.0%) | 0 (0.0%) | 8 (10.1%) |
   II | 2 (5.4%) | 27 (64.3%) | 1 (3.2%) | 29 (36.7%) |
   III | 35 (94.6%) | 7 (16.7%) | 30 (96.8%) | 42 (53.2%) |